Sudeep Pharma Fair Value
Sudeep Pharma (SUDEEPPHRM) average fair value is ₹410.69 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹648.8 (-36.7%), fair value range ₹61.25–₹1064.06. See SUDEEPPHRM book value comparison to compare market price against book value per share.
Fair Value Analysis Export
SUDEEPPHRM Fair Value vs Current Price — Valuation Summary
SUDEEPPHRM average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). For live price and a broader fundamental view, visit Sudeep Pharma stock price NSE.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
SUDEEPPHRM Fair Value Analysis — Data Sources & Coverage
Sudeep Pharma financial data sources, valuation methods applied and sector benchmarks used — 2025 financial year. Examine SUDEEPPHRM quarterly results for recent quarterly revenue, profit and EPS trends.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is from the previous year (2025).
SUDEEPPHRM vs Healthcare Sector Peers — P/E, P/B & Market Cap
Sudeep Pharma P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Jeena Sikho Lifecare | JSLL | 40.38 | 23.07 | ₹7,944 |
| Accretion Pharmaceuticals | ACCPL | 17.91 | 2.7 | ₹120 |
| Par Drugs & Chemical | PAR | 8.2 | 0.96 | ₹103 |
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
| Acutaas Chemicals | ACUTAAS | 62.6 | 13.49 | ₹22,359 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.